Justin C Brown1,2,3, Anita Giobbie-Hurder4, Rachel L Yung5, Erica L Mayer4, Sara M Tolaney4, Ann H Partridge4, Jennifer A Ligibel4. 1. Pennington Biomedical Research Center, Baton Rouge, Los Angeles, USA. 2. LSU Health Sciences Center, New Orleans School of Medicine, New Orleans, Los Angeles, USA. 3. Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, Los Angeles, USA. 4. Dana-Farber Cancer Institute, Boston, Massachusetts, USA. 5. Department of Medicine, University of Washington, Seattle, Washington, USA.
Abstract
OBJECTIVE: The Healthy Living and Eating After Cancer Trial demonstrated that a clinic-based weight loss program reduced body weight, as compared with a waitlist control group, over 15 weeks. Here we report the impact of the weight loss intervention on health-related quality-of-life outcomes at week 15, and maintenance of weight loss to week 30. METHODS: This trial randomized cancer survivors of solid tumors and hematologic malignancies (breast cancer: 76.7%) to a 15-week group-based weight loss program (n = 30) or a waitlist control group (n = 30). Participants were not blinded to group assignment. Participants completed a variety of health-related quality-of-life outcome measures at baseline and week 15. From week 15 to week 30, participants initially randomized to the weight loss program were followed with no additional intervention, and participants initially randomized to the waitlist control group commenced the weight loss program. RESULTS: Over the 15 weeks, the weight loss program improved physical functioning (6.2 ± 2.9; p = 0.02; d = 0.31) and reduced insomnia symptoms (-17.1 ± 7.4; p = 0.03; d = -0.30) as measured by the EORTC QLQ-C30, and sleep disturbance (-4.9 ± 1.6; p = 0.005; d = -0.40) as measured by PROMIS, compared to waitlist control. After a weight loss of 4.6 ± 3.9 kg, from week 15 to week 30, participants who were initially randomized to the weight loss program maintained their prior weight loss (+0.6 ± 3.5 kg) and participants who were initially randomized to the waitlist control group lost weight (-3.4 ± 2.9 kg; p < 0.001). CONCLUSIONS: In cancer survivors with overweight or obesity, a 15-week clinic-based weight loss program improved health-related quality-of-life outcomes and produced sustained weight loss to week 30.
OBJECTIVE: The Healthy Living and Eating After Cancer Trial demonstrated that a clinic-based weight loss program reduced body weight, as compared with a waitlist control group, over 15 weeks. Here we report the impact of the weight loss intervention on health-related quality-of-life outcomes at week 15, and maintenance of weight loss to week 30. METHODS: This trial randomized cancer survivors of solid tumors and hematologic malignancies (breast cancer: 76.7%) to a 15-week group-based weight loss program (n = 30) or a waitlist control group (n = 30). Participants were not blinded to group assignment. Participants completed a variety of health-related quality-of-life outcome measures at baseline and week 15. From week 15 to week 30, participants initially randomized to the weight loss program were followed with no additional intervention, and participants initially randomized to the waitlist control group commenced the weight loss program. RESULTS: Over the 15 weeks, the weight loss program improved physical functioning (6.2 ± 2.9; p = 0.02; d = 0.31) and reduced insomnia symptoms (-17.1 ± 7.4; p = 0.03; d = -0.30) as measured by the EORTC QLQ-C30, and sleep disturbance (-4.9 ± 1.6; p = 0.005; d = -0.40) as measured by PROMIS, compared to waitlist control. After a weight loss of 4.6 ± 3.9 kg, from week 15 to week 30, participants who were initially randomized to the weight loss program maintained their prior weight loss (+0.6 ± 3.5 kg) and participants who were initially randomized to the waitlist control group lost weight (-3.4 ± 2.9 kg; p < 0.001). CONCLUSIONS: In cancer survivors with overweight or obesity, a 15-week clinic-based weight loss program improved health-related quality-of-life outcomes and produced sustained weight loss to week 30.
Authors: Qiuling Shi; Tenbroeck G Smith; Jared D Michonski; Kevin D Stein; Chiewkwei Kaw; Charles S Cleeland Journal: Cancer Date: 2011-04-14 Impact factor: 6.860
Authors: Jennifer A Ligibel; Catherine M Alfano; Kerry S Courneya; Wendy Demark-Wahnefried; Robert A Burger; Rowan T Chlebowski; Carol J Fabian; Ayca Gucalp; Dawn L Hershman; Melissa M Hudson; Lee W Jones; Madhuri Kakarala; Kirsten K Ness; Janette K Merrill; Dana S Wollins; Clifford A Hudis Journal: J Clin Oncol Date: 2014-10-01 Impact factor: 44.544
Authors: Shiraz I Mishra; Roberta W Scherer; Paula M Geigle; Debra R Berlanstein; Ozlem Topaloglu; Carolyn C Gotay; Claire Snyder Journal: Cochrane Database Syst Rev Date: 2012-08-15
Authors: John W Apolzan; Elizabeth M Venditti; Sharon L Edelstein; William C Knowler; Dana Dabelea; Edward J Boyko; Xavier Pi-Sunyer; Rita R Kalyani; Paul W Franks; Preethi Srikanthan; Kishore M Gadde Journal: Ann Intern Med Date: 2019-04-23 Impact factor: 25.391
Authors: Gregory E Simon; Evette J Ludman; Jennifer A Linde; Belinda H Operskalski; Laura Ichikawa; Paul Rohde; Emily A Finch; Robert W Jeffery Journal: Gen Hosp Psychiatry Date: 2008 Jan-Feb Impact factor: 3.238
Authors: Richard P Troiano; David Berrigan; Kevin W Dodd; Louise C Mâsse; Timothy Tilert; Margaret McDowell Journal: Med Sci Sports Exerc Date: 2008-01 Impact factor: 5.411
Authors: Ronette L Kolotkin; Ross D Crosby; Richard E Gress; Steven C Hunt; Ted D Adams Journal: Surg Obes Relat Dis Date: 2009-01-31 Impact factor: 4.734